文章：

基线血液CD8+T细胞活化效能可区分非小细胞肺癌患者对免疫检查点抑制剂联合立体定向放疗的应答者与非应答者

Baseline Blood CD8+T Cell Activation Potency Discriminates Responders from Non-Responders to Immune Checkpoint Inhibition Combined with Stereotactic Radiotherapy in Non-Small-Cell Lung Cancer

原文发布日期：19 July 2024

DOI: 10.3390/cancers16142592

类型: Article

开放获取: 是

英文摘要：

Background: Tumor-infiltrating immune cells have been correlated with prognosis for patients treated with immune checkpoint inhibitor (ICI) treatment of various cancers. However, no robust biomarker has been described to predict treatment response yet. We hypothesized that the activation potency of circulating T cells may predict response to ICI treatment. Methods: An exploratory analysis was conducted to investigate the association between the response to immune checkpoint inhibition (ICI) combined with stereotactic radiotherapy (SBRT) and the potency of circulating T cells to be activated. Blood-derived lymphocytes from 14 patients were stimulated ex vivo with, among others, Staphylococcal enterotoxin B (SEB) and compared to healthy controls (HCs). Patients were grouped into responders (>median progression free survival (PFS)) and non-responders (

摘要翻译： 

背景：肿瘤浸润免疫细胞与多种癌症患者接受免疫检查点抑制剂（ICI）治疗的预后相关。然而，目前尚未发现能够可靠预测治疗反应的生物标志物。我们假设循环T细胞的活化能力可能预测ICI治疗的反应。方法：本研究进行探索性分析，旨在探究免疫检查点抑制剂联合立体定向放射治疗（SBRT）的治疗反应与循环T细胞活化能力之间的关联。从14例患者采集血液来源淋巴细胞，在体外使用金黄色葡萄球菌肠毒素B（SEB）等进行刺激，并与健康对照（HCs）进行比较。根据无进展生存期（PFS）中位值将患者分为应答组（>中位PFS）和无应答组（<中位PFS）。采用流式细胞术检测CD4+和CD8+T细胞在刺激后T细胞活化标志物CD69及细胞内细胞因子（IL-2、IFNγ、TNFα）的表达水平。同时，通过Luminex技术测定血清中BAFF、IFNγ和IL-2受体（sIL-2R）的水平。结果：基线状态下，经SEB体外刺激后，应答组较无应答组显示出更高比例的活化CD8+T细胞（15.8% vs. 3.5%，p<0.01）和IL-2+CD69+CD8+T细胞（8.8% vs. 2.9%，p=0.02）。同时测定的血清细胞因子水平在两组间无显著差异。结论：通过体外刺激后细胞内细胞因子产生能力测定的基线血液CD8+T细胞活化能力，是区分SBRT联合ICI治疗应答者与无应答者的潜在生物标志物。

原文链接：

Baseline Blood CD8+T Cell Activation Potency Discriminates Responders from Non-Responders to Immune Checkpoint Inhibition Combined with Stereotactic Radiotherapy in Non-Small-Cell Lung Cancer